SFM
CGEM icon

Sphera Funds Management’s Cullinan Oncology CGEM Stock Holding History

Sphera Funds Management’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-205,000
Closed -$2.5M – 117
2024
Q4 		$2.5M Buy
205,000
+19,129
+10% +$275K 0.45% 72
2024
Q3 		$3.11M Buy
+185,871
New +$3.3M 0.5% 58

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Sphera Funds Management's CGEM Position: Q1 2025 in Review

Sphera Funds Management sold out of Cullinan Oncology (CGEM) in Q1 2025, closing a stake of 205,000 shares — an estimated $2.5M sold.

Sphera Funds Management first reported a position in CGEM in Q3 2024 and held it in 2 quarters. The position peaked at $3.11M in Q3 2024. 148 funds tracked by Wall St. Rank hold CGEM as of Q1 2025.

  • Sphera Funds Management reported no remaining Cullinan Oncology position as of Q1 2025 after selling out during the quarter.
  • Sphera Funds Management sold 205,000 Cullinan Oncology shares in Q1 2025, an estimated $2.5M.
  • Sphera Funds Management first reported a position in Cullinan Oncology in Q3 2024 and held it in 2 quarters.
  • Sphera Funds Management's Cullinan Oncology position peaked at $3.11M in Q3 2024.
  • 148 funds tracked by Wall St. Rank held Cullinan Oncology as of Q1 2025.

Based on Sphera Funds Management's 13F filing for Q1 2025, filed 15 May 2025.